{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T05:03:48Z","timestamp":1779771828756,"version":"3.53.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.amjmed.2026.02.049","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T09:28:35Z","timestamp":1773048515000},"page":"854-866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sodium-glucose cotransporter 1&2 inhibitors in heart failure and diabetes mellitus: From foundational therapy to emerging frontiers"],"prefix":"10.1016","volume":"139","author":[{"given":"Prakash","family":"Deedwania","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2626-8219","authenticated-orcid":false,"given":"Akshat","family":"Banga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.amjmed.2026.02.049_bib0001","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"},{"issue":"10354","key":"10.1016\/j.amjmed.2026.02.049_bib0002","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.amjmed.2026.02.049_bib0003","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.amjmed.2026.02.049_bib0004","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.amjmed.2026.02.049_bib0005","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.amjmed.2026.02.049_bib0006","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure","volume":"79","author":"Heidenreich Paul","year":"2022","journal-title":"JACC"},{"issue":"37","key":"10.1016\/j.amjmed.2026.02.049_bib0007","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.amjmed.2026.02.049_bib0008","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amjmed.2026.02.049_bib0009","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amjmed.2026.02.049_bib0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13300-013-0042-y","article-title":"Sodium glucose Co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes mellitus","volume":"4","author":"Bays","year":"2013","journal-title":"Diabetes Ther"},{"issue":"9","key":"10.1016\/j.amjmed.2026.02.049_bib0011","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1517\/14728222.2016.1168808","article-title":"Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus","volume":"20","author":"Song","year":"2016","journal-title":"Expert Opin Ther Targets"},{"issue":"4","key":"10.1016\/j.amjmed.2026.02.049_bib0012","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/jdi.13255","article-title":"Sodium-glucose cotransporters: functional properties and pharmaceutical potential","volume":"11","author":"Sano","year":"2020","journal-title":"J Diabetes Investig"},{"issue":"15","key":"10.1016\/j.amjmed.2026.02.049_bib0013","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.amjmed.2026.02.049_bib0014","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.amjmed.2026.02.049_bib0015","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.amjmed.2026.02.049_bib0016","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.amjmed.2026.02.049_bib0017","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40262-015-0264-4","article-title":"Pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"54","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.amjmed.2026.02.049_bib0018","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/ajhp\/zxaf044","article-title":"KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: a primer on what pharmacists need to know","volume":"82","author":"Awdishu","year":"2025","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.amjmed.2026.02.049_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1494882","article-title":"SGLT2 inhibitors for alleviating heart failure through non-hypoglycemic mechanisms","volume":"11","author":"Chen","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"10.1016\/j.amjmed.2026.02.049_bib0020","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/bcp.14248","article-title":"Effects of the dual sodium\u2013glucose linked transporter inhibitor, licogliflozin versus placebo or empagliflozin in patients with type 2 diabetes and heart failure","volume":"86","author":"de Boer","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.amjmed.2026.02.049_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2025.103149","article-title":"SGLT2 inhibitors and cardiac fibrosis: a comprehensive review","volume":"50","author":"Karakasis","year":"2025","journal-title":"Curr Probl Cardiol"},{"issue":"5","key":"10.1016\/j.amjmed.2026.02.049_bib0022","article-title":"SGLT2 inhibitors and kidney protection: mechanisms beyond tubuloglomerular feedback","volume":"5","author":"Upadhyay","year":"2024","journal-title":"Kidney 360"},{"key":"10.1016\/j.amjmed.2026.02.049_bib0023","series-title":"StatPearls","article-title":"Sodium-glucose transport 2 (SGLT2) inhibitors","author":"Padda","year":"2025"},{"issue":"1","key":"10.1016\/j.amjmed.2026.02.049_bib0024","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-024-02491-w","article-title":"SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling","volume":"23","author":"G\u00f6pel","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"24","key":"10.1016\/j.amjmed.2026.02.049_bib0025","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.amjmed.2026.02.049_bib0026","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.amjmed.2026.02.049_bib0027","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.amjmed.2026.02.049_bib0028","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.amjmed.2026.02.049_bib0029","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","article-title":"Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2026.02.049_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080925","article-title":"SGLT-2 inhibitors and mortality among patients with heart failure with reduced ejection fraction: linked database study","volume":"387","author":"Svanstr\u00f6m","year":"2024","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.amjmed.2026.02.049_bib0031","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-025-02924-0","article-title":"Type 2 diabetes, sodium-glucose cotransporter-2 inhibitors and cardiovascular outcomes: real world evidence versus a randomised clinical trial","volume":"24","author":"Yazdanfard","year":"2025","journal-title":"Cardiovasc Diabetol"},{"issue":"23","key":"10.1016\/j.amjmed.2026.02.049_bib0032","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjmed.2026.02.049_bib0033","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42078","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in patients with type 2 diabetes and other risk factors for cardiovascular disease","volume":"5","author":"Bhattarai","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.amjmed.2026.02.049_bib0034","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/ehf2.15036","article-title":"Meta-analysis of sotagliflozin, a dual sodium-glucose-cotransporter 1\/2 inhibitor, for heart failure in type 2 diabetes","volume":"12","author":"Bantounou","year":"2025","journal-title":"ESC Heart Fail"},{"issue":"4","key":"10.1016\/j.amjmed.2026.02.049_bib0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.5135","article-title":"SGLT2 inhibitors, functional capacity, and quality of life in patients with heart failure","volume":"7","author":"Gao","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.amjmed.2026.02.049_bib0036","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1111\/jgs.70143","article-title":"SGLT2 inhibitors in older adults with cardiovascular disease: a systematic review and meta-analysis","volume":"73","author":"Minami","year":"2025","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.amjmed.2026.02.049_bib0037","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s41999-023-00752-7","article-title":"Diuretics, SGLT2 inhibitors and falls in older heart failure patients: to prescribe or to deprescribe? A clinical review","volume":"14","author":"van Poelgeest","year":"2023","journal-title":"Eur Geriatr Med"},{"issue":"11","key":"10.1016\/j.amjmed.2026.02.049_bib0038","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/phar.4620","article-title":"ECLIPSES: early initiation of sodium glucose cotransporter-2 inhibitors for cardiovascular protection in patients with type 2 diabetes following acute coronary syndrome and subsequent coronary artery bypass graft surgery","volume":"44","author":"Makortoff","year":"2024","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.amjmed.2026.02.049_bib0039","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.amjmed.2026.02.049_bib0041","article-title":"Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients","author":"Wu","year":"2025","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.amjmed.2026.02.049_bib0042","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2023-003666","article-title":"Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors","volume":"11","author":"Chow","year":"2023","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"14","key":"10.1016\/j.amjmed.2026.02.049_bib0040","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/CIRCULATIONAHA.117.031227","article-title":"Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor","volume":"137","author":"Udell","year":"2018","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.amjmed.2026.02.049_bib0043","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1161\/CIRCULATIONAHA.122.060823","article-title":"\u201cDip\u201d in eGFR: stay the course with SGLT-2 inhibition","volume":"146","author":"Umanath","year":"2022","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.amjmed.2026.02.049_bib0044","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations","volume":"7","author":"Yau","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1016\/j.amjmed.2026.02.049_bib0045","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bja.2024.05.004","article-title":"Risk of perioperative discontinuation of SGLT2 inhibitors","volume":"133","author":"Oosterom-Eijmael","year":"2024","journal-title":"Br J Anaesth"},{"issue":"2","key":"10.1016\/j.amjmed.2026.02.049_bib0046","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/dom.16061","article-title":"Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: a cause for concern?","volume":"27","author":"Milder","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.amjmed.2026.02.049_bib0047","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.amjmed.2026.02.049_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.kint.2022.06.013","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.amjmed.2026.02.049_bib0049","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jamacardio.2022.4348","article-title":"Population-level implications of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction in the US","volume":"8","author":"Talha","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1016\/j.amjmed.2026.02.049_bib0050","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1002\/ehf2.15398","article-title":"Digital implementation strategy to increase SGLT2 inhibitor uptake in heart failure: study design of EMAIL-HF","volume":"12","author":"Elmegaard","year":"2025","journal-title":"ESC Heart Fail"},{"issue":"7","key":"10.1016\/j.amjmed.2026.02.049_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.101879","article-title":"Implementing a cardiology quality incentive program to improve guideline-directed medical therapy","volume":"4","author":"Cho","year":"2025","journal-title":"JACC Adv"},{"issue":"7","key":"10.1016\/j.amjmed.2026.02.049_bib0052","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamacardio.2021.0496","article-title":"Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure\u2014optimizing therapy with the need for speed","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"9","key":"10.1016\/j.amjmed.2026.02.049_bib0053","article-title":"Guideline-directed medical therapy use in the STRONG-HF trial","volume":"18","author":"Zhang","year":"2025","journal-title":"Circulation"},{"issue":"Supplement_2","key":"10.1016\/j.amjmed.2026.02.049_bib0054","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad655.2819","article-title":"Comparison of sodium-glucose cotransporter-2 (SGLT2) inhibitors to reduce cardiovascular and renal outcomes: a network meta-analysis of randomized controlled trials","volume":"44","author":"Kani","year":"2023","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.amjmed.2026.02.049_bib0055","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/FJC.0000000000001747","article-title":"Rationale and design of the SOTA-THROMBOSIS trial (ATRU-VI): antithrombotic activities of sotagliflozin compared with empagliflozin","volume":"86","author":"Requena-Ib\u00e1\u00f1ez","year":"2025","journal-title":"J Cardiovasc Pharmacol"},{"issue":"9","key":"10.1016\/j.amjmed.2026.02.049_bib0056","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.jchf.2024.04.018","article-title":"Cost-effectiveness of sotagliflozin in SOLOIST-WHF","volume":"12","author":"Weintraub","year":"2024","journal-title":"JACC Heart Fail"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326001774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326001774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:25:49Z","timestamp":1779769549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934326001774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0002934326001774"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.02.049","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-glucose cotransporter 1&2 inhibitors in heart failure and diabetes mellitus: From foundational therapy to emerging frontiers","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.02.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}